Compare Eli Lilly And Co (LLY) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs iShares 10 20 Year Treasury Bond ETF — how do they compare? Eli Lilly And Co trades at $1,176.52 (market cap $1.04T), while iShares 10 20 Year Treasury Bond ETF trades at $92.13 (market cap $11.02B). The key difference: Eli Lilly And Co is far larger — about 94.4× iShares 10 20 Year Treasury Bond ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while iShares 10 20 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and iShares 10 20 Year Treasury Bond ETF for 60 Days on average.
| LLY | TLH | |
|---|---|---|
Market Cap | $1.04T | $11.02B |
Volume | 3,064,878 | 6,609,157 |
Sector | Health | Fixed Income |
52-Week High | $1.28K | $105.36 |
52-Week Low | $799.57 | $91.34 |
Typical Hold Time | 93 Days | 60 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
TLH, the iShares 10-20 Year Treasury Bond ETF, trades at $91.45, down 0.12% with a bearish technical outlook. The ETF has seen unusually high trading volume recently, with 2.3 million shares traded on September 30, 2026. Bond market volatility has driven significant price movements as 10-year Treasury yields reached multi-decade highs above 5% before pulling back. The fund maintains regular dividend distributions, with recent payments ranging from $0.36 to $0.38 per share.
The outlook remains challenging amid persistent bond market volatility and expectations of higher-for-longer interest rates. Rising yields pressure bond prices, creating headwinds for TLH, though current levels may attract income-seeking investors. Key risks include further Fed tightening and inflation concerns, while potential catalysts include economic slowdown or Fed policy shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
